Free tool
FAERS Monitor: Seysara
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 209521 or its brand name (Seysara, Sarecycline Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
200
Serious
39
20% of reports
Hospitalization
15
Death reported
0
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- headache24
- drug ineffective14
- dizziness13
- vision blurred11
- rash9
- off label use8
- product dose omission issue8
- pruritus8
- condition aggravated7
- fatigue7
- nausea7
- anxiety6
- erythema6
- migraine6
- seizure6
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2019 | 35 |
| 2020 | 27 |
| 2021 | 24 |
| 2022 | 21 |
| 2023 | 23 |
| 2024 | 30 |
| 2025 | 12 |
| 2026 | 28 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,959 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| vision blurredSignal | 11 | 8.4 | 4.7 | 65 |
| migraineSignal | 6 | 6.6 | 3.0 | 23 |
| seizureSignal | 6 | 5.5 | 2.5 | 18 |
| headacheSignal | 24 | 4.0 | 2.8 | 53 |
| erythemaSignal | 6 | 3.1 | 1.4 | 6 |
| product dose omission issueSignal | 8 | 2.9 | 1.5 | 8 |
| dizzinessSignal | 13 | 2.7 | 1.6 | 13 |
| condition aggravatedSignal | 7 | 2.4 | 1.2 | 5 |
| anxiety | 6 | 2.2 | 1.0 | 3 |
| pruritusSignal | 8 | 2.2 | 1.1 | 4 |
| rashSignal | 9 | 2.2 | 1.1 | 5 |
| drug ineffective | 14 | 1.1 | 0.7 | 0 |
| off label use | 8 | 1.0 | 0.5 | 0 |
| fatigue | 7 | 0.9 | 0.5 | 0 |
| nausea | 7 | 0.9 | 0.4 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.